Figure 4
Figure 4. AQX-MN100 has the same biologic activities as AQX-016A. (A) Structures of AQX-MN100 and AQX-016A. (B) AQX-MN100 activates SHIP1 enzyme activity in vitro. Assays performed as in Figure 1A. (C) AQX-MN100 inhibits TNFα production from LPS stimulated SHIP1+/+ but not SHIP1−/− BMmφs. Cells and treatments were as described in Figure 2A. (D) AQX-MN100 inhibits LPS-induced plasma TNFα levels in mice. Mice were treated as in Figure 2E. (E) AQX-MN100 inhibits DNFB-induced neutrophil-specific myeloperoxidase (MPO) in sensitized mice. Mice were sensitized as in Figure 2F, and vehicle or AQX-MN100 applied to pairs of ears prior to DNFB challenge. Some mice were not challenged with DNFB (no DNFB). Ears were harvested, and MPO levels were determined. P < .02 for the AQX-MN100 versus the vehicle-treated groups. Data are expressed as the mean (±SEM) and are representative of 3 independent experiments.

AQX-MN100 has the same biologic activities as AQX-016A. (A) Structures of AQX-MN100 and AQX-016A. (B) AQX-MN100 activates SHIP1 enzyme activity in vitro. Assays performed as in Figure 1A. (C) AQX-MN100 inhibits TNFα production from LPS stimulated SHIP1+/+ but not SHIP1−/− BMmφs. Cells and treatments were as described in Figure 2A. (D) AQX-MN100 inhibits LPS-induced plasma TNFα levels in mice. Mice were treated as in Figure 2E. (E) AQX-MN100 inhibits DNFB-induced neutrophil-specific myeloperoxidase (MPO) in sensitized mice. Mice were sensitized as in Figure 2F, and vehicle or AQX-MN100 applied to pairs of ears prior to DNFB challenge. Some mice were not challenged with DNFB (no DNFB). Ears were harvested, and MPO levels were determined. P < .02 for the AQX-MN100 versus the vehicle-treated groups. Data are expressed as the mean (±SEM) and are representative of 3 independent experiments.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal